Sentences with phrase «myeloma patient study»

«Multiple myeloma patient study shows promise for natural killer cells: Phase I study included combination with high - dose chemotherapy and stem cell transplantation.»

Not exact matches

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

To participate in the study, which concludes in July 2020, patients must be 18 years or older and have a histological - or cytological - proven diagnosis of a malignancy in the lung, breast, head and neck, genitourinary organs or ovaries or multiple myeloma.

«Choice of medical center impacts life expectancy of multiple myeloma patients, study shows.»

«These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher disease and others with precursors for myeloma.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

These studies enrolled a total of 12,361 patients diagnosed with a variety of cancers, including lung, breast, skin, and prostate, as well as blood cancers such as leukemia, lymphoma, and myeloma.

While some previous studies found that maintenance lenalidomide after autologous hematopoietic stem cell transplant improved overall survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.

«There are clearly molecular differences between African - American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients,» said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

A new study published online by JAMA Oncology examines the assessment of minimal residual disease in patients newly treated for multiple myeloma as a factor in survival outcomes.

Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for another reason, according to a study published online by JAMA Oncology.

The authors speculate the reasons for the prolonged survival in their study is that patients with MGUS are evaluated more often for signs of progression to MM and may be diagnosed and started on therapy for myeloma at an earlier stage.

The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.

Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana - Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH).

«This study presents a novel strategy for treating multiple myeloma, and we hope to bring it to patients as part of a phase I clinical trial as soon as possible,» Hofmeister says.

The combination of pomalidomide plus low - dose dexamethasone showed efficacy with high rates of disease control in relapsed or refractory multiple myeloma patients with severe renal impairment, according to the results of a phase II study.

CRP Levels Before Transplant Linked With Survival in Multiple Myeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSMyeloma: According to a new study, patients with an elevation in C - reactive protein (CRP) prior to an autologous stem cell transplantation (ASCT) for multiple myeloma experienced a worse overall survival (OSmyeloma experienced a worse overall survival (OS) rate.

December 6, 2011 Drug combination highly effective for newly diagnosed myeloma patients, study finds A three - drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.

Darbepoietin - Alfa after High - Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study